Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

Study Overview
=================
Brief Summary
-----------------
The project topic consists on re-conciliating the fine tuners of the gene expression microRNAs and the immunopathogenic occasions responsible for skin disorders in context of skin infection and inflammation such as psoriasis. The skin is a network of effector cells and molecular mediators that constitute a highly sophisticated Skin Immune System (SIS) described by Jan D Bos in 1986. The cutaneous homeostasis maintenance is dependent on the cross talk between several immune sentinels present in the different compartments of the skin as well as the interplay between innate and adaptive immune responses. The whole is under the control of gene regulation. However, cutaneous homeostasis disruption occurs when the SIS safe framework erroneously sends aggravation signals due to gene regulation disbalance via inflammatory cellular and molecular mediators into the site of infection causing chronic inflammation characterized by thick red irritated skin lesions. The latter was showed to have a characteristic microRNA (regulators of gene expression) signature.

Official Title
-----------------
Comparative Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Procedure: Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women between 18 and 75 Clinical diagnosis of chronic active psoriasis in non-pustular plaque Treated locally with topical corticosteroids Exclusion Criteria: Patient who did not give express consent to participate No affiliation to a social security scheme Patient treated systemically Thrombocytopenic patient Patient known to be HIV-positive Septic patient Patient with only facial lesions Patient with psoriasis with joint involvement Patient participating in another study Patient protected under the law (under guardianship or trusteeship) Pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient with lesional skin<br>the sample will be taken by superficial cutaneous biopsy in psoriasic patients | Procedure: Biopsy<br>* the sample will be taken by superficial cutaneous biopsy in psoriasic patients<br>|
| No Intervention: Patients with healthy skin<br>the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase Ratio | Increase ratio between relative expression of different genes (miR-21 and InterLeukin-22) of psoriatic lesional skin and non-psoriatic skin | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Psoriasis Area Severity Index and miR-21 expression |  | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psoriasis, IL-22, miR-21